Incidence and Outcomes from Transplant-Associated Thrombotic Microangiopathy in Allogeneic Pediatric Hematopoietic Stem Cell Transplant Recipients before and after the Introduction of Eculizumab: A Single Institution Experience from Oregon Health & Science University

Kimberly M Lerner, Patrick DeMartino(Oregon Health & Science University), Evan Shereck(Oregon Health & Science University), Bill H. Chang(Oregon Health & Science University), Eneida R. Nemecek(Oregon Health & Science University), Richard T. Maziarz(Oregon Health & Science University)
Transplantation and Cellular Therapy
March 1, 2022
10.1016/s2666-6367(22)00333-5
Cited by 0

Related Papers

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.
|PubMed|1996|645
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577